The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
The company has predominantly built a portfolio into veterinary products
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
Port chairpersons have been asked to personally supervise logistic operations to ensure unhindered movement of such consignments for berthing of such vessel on top priority in the port
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
Subscribe To Our Newsletter & Stay Updated
